UBS Global Biopharma Conference - BIOAGE LABS INC
Explicit Guidance:
- Clinical Data Readouts: Targeting Phase 2 trial (QUAL-CV) data readout for BGE-102 at the end of 2024; Phase 1 IND filing for the APJ agonist program by the end of 2024; Phase 2 readout for Quell DME (Diabetic Macular Edema) in the second half of 2025.
- Financials: Cash position of $350 million+ providing a runway extending through 2029.
- Capital Allocation: Funds currently allocated to complete NLRP3 trials (QUAL-CV, Quell DME), Proof of Concept (PoC) for an additional NLRP3 indication, and APJ programs through PoC.
Business-Segment Outlook:
- NLRP3 (BGE-102) Strategy Pivot: Shifting primary focus from Cardiovascular (ASCVD/Arterial imaging) to Ophthalmology (starting with DME as a "beachhead") and a new, unannounced indication where upstream biology is de-risked. ASCVD outcomes trials remain a potential future path contingent on competitor data (e.g., Artemis results or LEO/Ventix signals).
- Ophthalmology Pipeline:
- Diabetic Macular Edema (DME): Oral BGE-102 monotherapy and combination with VEGF inhibitors; aiming to replicate the ~4-letter BCVA improvement seen with IL-6 neutralization, with a 3-month dosing window.
- Future Indications: Potential expansion into Geographic Atrophy (GA) and Uveitic Macular Edema pending DME success and PK/PD validation in the eye.
- APJ Agonists: Advancing two parallel programs (oral and parenteral) targeting obesity and muscle preservation. Preclinical data suggests potential to double weight loss and fully restore body composition when combined with GLP-1s. Awaiting IND filing to debut the program.
- Platform & Partnerships: Leveraging human aging data in collaboration with Lilly (therapeutic antibody development) and Novartis (target discovery linking exercise benefits to longevity).
Market and Competitive Outlook:
- Differentiation vs. NLRP3 Competitors: BGE-102 utilizes a novel binding site distinct from ATPase pocket inhibitors (e.g., Pfizer), enabling 98% trough inhibition of IL-1β and potential to inhibit/assemble inflammasome states. Differentiated by superior tissue distribution (brain, retina) compared to historical programs.
- Therapeutic Efficacy Expectations: Positioned to capture IL-1β, IL-18, and pyroptotic cell death upstream of IL-6, potentially offering incremental efficacy over IL-6 inhibitors (like Zilteb) which may act too far downstream in the inflammatory cascade.
- Adoption in DME: Targeting two underserved patient segments: those resistant to intravitreal injections ("watch and wait") and VEGF-incomplete responders needing a second mechanism of action.
Macro / Industry Outlook:
- Investor Sentiment Impact: The failure of the Zeus trial (IL-6 target) has shifted investor appetite away from 5-year, $500M+ cardiovascular outcomes trials for smaller biotechs, necessitating a strategic pivot to earlier-stage, de-risked indications where POC is achievable.
- Regulatory/Competitive Watch: Monitoring competitor data (Lily's Ventix NLRP3 program, Artemis trial) for signals that could catalyze a return to cardiovascular outcomes trials.
- Safety Profile: Anticipating "placebo-like tolerability" for BGE-102 based on Phase 1 data, contrasting with the liver safety signals of prior APJ programs.
Strategic Initiatives:
- Clinical Advancement: Initiating Phase 2 QUAL-CV trial to define dose-response relationships between IL-1β suppression and metabolic markers (CRP, IL-6, fibrinogen) over 3 months.
- Target De-risking: Focusing on indications where IL-1 and IL-6 neutralization has shown clinical efficacy to minimize development risk.
- Chemistry Optimization: Developing a novel chemotype for the APJ agonist with a <100mg daily dose to mitigate liver safety risks associated with prior higher-dose (300mg BID) programs.
Risks and Headwinds to Outlook:
- Clinical Trial Failure: The possibility that DME or other NLRP3 indications may fail to meet efficacy endpoints, potentially stalling the ophthalmology expansion.
- Strategic Pivot Delays: If competitor data (e.g., Ventix or Artemis) does not show a definitive signal, the company may miss a window to capitalize on the NLRP3 cardiovascular narrative.
- Safety Signals: Potential for unforeseen safety issues in the new APJ chemotype, though the new design specifically targets lower dosing to avoid idiosyncratic liver injury.
- Funding Runway: While $350M extends to 2029, the timeline for value creation relies heavily on successful readouts in late 2024 and 2025.
Management Tone on the Future:
- Confident & Adaptive: Management expresses high confidence in the "de novo" NLRP3 chemistry and tissue distribution profile. There is a clear, pragmatic shift in strategy post-Zeus data, moving from long-duration cardiovascular trials to faster-turnaround POC studies in ophthalmology.
- Optimistic on Mechanism: Strong belief that upstream NLRP3 inhibition offers biological advantages (pyroptosis inhibition) over downstream IL-6 inhibition, driving the expectation of superior efficacy in DME.
- Cautious on Timing: Hedges regarding the APJ filing date ("filing our IND... by end of year") and the specific timing of the DME readout ("end of next year"), indicating flexibility in the schedule based on internal validation.
Miscellaneous:
- Clinical Trial Design Details: Quell DME trial is powered to show a 4-letter improvement in BCVA, comparing monotherapy and combination with VEGF, with a 3-month treatment window to capture maximum separation.
- Data Points: Phase 1 showed 86% reduction in CRP, concordant IL-6/fibrinogen reductions, and robust CSF and retinal penetration (via NHP data and lumbar punctures).
- Preclinical Models: Mouse models of profound hyperglycemia showed complete correction of diabetic retinopathy and restoration of microvascular integrity via NLRP3 inhibition.
- Company
- BIOAGE LABS INC
- Keywords
- BIOAGE LABS INC